Articles tagged with: Carfilzomib
Onyx Pharmaceuticals, the South San Francisco, California-based company that developed and now markets Kyprolis (carfilzomib), announced yesterday evening that it is being acquired by Amgen.
Amgen (NASDAQ:AMGN), which is based outside of Los Angeles, is the world’s largest biotech company.
Within the multiple myeloma community, Amgen is known most for its anemia medications – Aranesp (darbepoetin alfa) and Epogen (epoetin alfa, also marketed as Procrit and Eprex) – as well as its drugs that increase the body’s production of white blood cells – Neupogen (filgrastim) and
Physicians and researchers have started gathering for the 18th Congress of the European Hematology Association (EHA), which will take place in Stockholm this year. The first education and poster sessions of the meeting will take place tomorrow, Friday, June 14. Additional sessions of various kinds are scheduled for both days of the weekend, until the meeting ends early Sunday afternoon (European time).
The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related diseases, including multiple myeloma.
The EHA …
This year’s meeting of the American Society of Clinical Oncology (ASCO) was held May 31 through June 4 in Chicago.
During the meeting, The Beacon published daily updates that provided overviews of the important multiple myeloma findings presented during the meeting.
Now that the meeting has concluded, the focus shifts to the bigger picture: What were the key findings of the meeting? Were there results with immediate implications for the treatment of multiple myeloma? Did the research at the meeting represent a major step forward for myeloma …
This year’s American Society of Clinical Oncology (ASCO), which was held in Chicago, began on Friday and concluded on Tuesday.
Monday was the busiest day at the meeting with regard to myeloma research. It featured a session of oral presentations in the morning and a poster session in the afternoon.
This update summarizes the myeloma-related studies presented during the afternoon poster session, which was the final myeloma-related session of the meeting. An earlier article covered the findings from the oral presentations that were given in the morning.
Most of …
This year’s annual meeting of the American Society of Clinical Oncology (ASCO) came to an end yesterday in Chicago.
Monday was the busiest day with regard to myeloma-related research. The day started with an oral presentation session that included eight talks about important new myeloma-related research. A poster session in the afternoon included several posters about myeloma-related research.
This article summarizes the most important findings from Monday's oral presentation session. A later article will cover the findings from the afternoon poster session.
The content in our daily updates is based …